This study highlights novel genotype-driven metabolic adaptations in PM, laying the groundwork for targeted interventions ...

There has been considerable progress in the management of pleural mesothelioma since the initial ASCO clinical practice guideline was published in 2018. Updated evidence-based recommendations were ...

Merck's heavy reliance on Keytruda continues to grow, with the drug nearing 50% of total sales and limited growth from other products. Read why MRK is a Buy.

Merck said on Wednesday it will acquire UK-based Verona Pharma for about $10 billion, gaining a promising respiratory treatment as it faces pressure to diversify beyond its blockbuster cancer drug ...

Merck's growing pipeline, with nearly 20 new launches ahead, is set to reshape its portfolio as Keytruda's 2028 patent expiry nears.

Formycon currently anticipates that FYB206 could enter the U.S. market after Keytruda’s exclusivity expires in 2029, and in the EU after 2030.

In this analysis, we explore the potential upside for Merck despite its short-term hurdles.

CNBC's Angelica Peebles reports on themes emerging in the pharma space. Donald Trump announces deal to end Republican revolt Kathy Bates’ Emmys nod says a lot about the state of TV Nurse who ...

While Merck faces the inevitable Keytruda patent cliff in 2028, the company is positioning itself for continued growth through strategic diversification and pipeline expansion. Earlier this month ...

Merck will buy UK-based Verona Pharma for about $10 billion, the companies said on Wednesday, strengthening the U.S. drugmaker's respiratory treatments as part of efforts to reduce dependence on its ...

Keytruda, the world's top-selling drug with nearly $30 billion in revenue last year, is nearing key patent expirations from 2028, and Merck has doubled down on efforts to reshape its portfolio.

The Best Biotech Stocks to Buy Thanks to rapid innovation and strong product launches, some biotech stocks look attractive.